Specialised Therapeutics to commercialize Incyte’s Opzelura in Australia
We haven't written up this one. Seeking Alpha News has the full story — the link below goes straight to it.
More in Finance & Markets
Moneyview IPO Opens On September 24, Price Band Fixed At ₹32–₹34 Per Share
Mumbai: Digital lending platform Moneyview Ltd will launch its ₹1,092-crore initial public offering on September 24, offering investors an opportunity to participate in one of India’s growing fintech…
Mutui, l’impatto dei tassi: rincaro medio fino a 540 euro all’anno sui nuovi contratti
Quasi 13.500 euro in più nell’arco di 25 anni, pari a 540 euro l’anno. È il maggior costo stimato per chi stipula a ottobre un mutuo da 130mila euro rispetto...
NMDC shares rally 2% after company sets target to achieve net-zero operational emissions by 2047
NMDC shares rallied up to 2% on Monday to Rs 80.85 after setting a target to achieve net-zero operational emissions by 2047.
Repsol, Inditex, Mapfre y Logista para reforzar la cartera
Manuel Pinto, director de análisis de XTB, es positivo con las perspectivas de algunos valores españoles más allá de la banca.
Australia to rely on AI to spur economy in decades ahead
Australia’s economic growth is projected to slow to 2% through the mid-2060s, while declining population growth makes productivity gains increasingly important.